

# Efficacy and safety of low-dose IL-2 (Id-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)

<https://neurodegenerationresearch.eu/survey/efficacy-and-safety-of-low-dose-il-2-id-il-2-as-a-treg-enhancer-for-controlling-neuro-inflammation-in-newly-diagnosed-amyotrophic-lateral-sclerosis-als-patients-mirocals/>

## Principal Investigators

Prof Nigel Leigh

## Institution

University of Sussex

## Contact information of lead PI

### Country

United Kingdom

## Title of project or programme

Efficacy and safety of low-dose IL-2 (Id-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)

## Source of funding information

MND Association

## Total sum awarded (Euro)

€ 429,029

## Start date of award

01/09/2016

## Total duration of award in years

3

## Keywords

Research Abstract

Further information available at:

## Types:

Investments < €500k

**Member States:**

United Kingdom

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A